A seasoned biopharma operator with a technical background in vaccines, Reichman took over a struggling firm, rebranded it from BiondVax to Scinai, and pivoted toward a dual strategy of internal drug development and boutique CDMO services.
Early Life: Born and educated in Israel, Reichman developed a strong technical foundation early in his career, including early roles at NeuroDerm.
First Break: His tenure as a senior executive at GSK Vaccines, specifically leading global engineering and asset management, served as his primary career launchpad into high-level leadership.
Path to CEO: Following his exit from GSK, Reichman was appointed CEO of BiondVax (now Scinai) in 2021 to lead a structural turnaround. He navigated the company through a complex rebranding, a major shift in technical focus toward inflammation and immunology, and the launch of a commercial CDMO arm to stabilize finances.
Original Vision: To transform the company from a single-asset vaccine developer into a sustainable, multifaceted biopharmaceutical business that balances long-term clinical pipeline innovation with near-term revenue-generating manufacturing services.
Amir Reichman brought a pragmatic, engineering-focused leadership style to Scinai. Facing a difficult R&D landscape, he did not rely solely on the pipeline, but aggressively diversified the business model by utilizing the company's manufacturing facility for boutique CDMO services. This strategy has been central to his efforts to keep the company funded and operational amidst the high-burn requirements of early-stage biotech development. His career journey highlights a transition from technical operations in global conglomerates like GSK and Novartis to a hands-on, turnaround executive role in the small-cap biotech sector.
turnaround expertbiopharma operatortechnical leader
